Literature DB >> 1158041

Glucagon response to arginine after treatment of diabetes mellitus.

A Ohneda, S Ishii, K Horigome, S Yamagata.   

Abstract

To investigate the aminogenic glucagon response in diabetes mellitus, arginine infusion tests were carried out on twenty-four diabetic patients before and after treatment. Eleven healthy men served as a control group. Plasma glucagon was measured by radioimmunoassay using an antiserum, G21, specific for pancreatic glucagon. Out of twenty-four patients, five were treated with diet alone, eight with sulfonylurea, and eleven with insulin. In all these diabetic groups, the glucose tolerance improved after treatment for diabetes mellitus, while the insulin response to the glucose did not show any remarkable change. The fasting levels of the plasma glucagon did not differ from that of the normal subjects both before and after treatment. Hyperresponsiveness of the plasma glucagon to arginine infusion was observed in all diabetic groups, in comparison with that of the normal controls. The exaggerated response of the plasma glucagon to arginine was lowered following appropriate treatment in each diabetic group. However, as far as the changes in glucagon area during the arginine test are concerned, the aminogenic hyperresponsiveness of the plasma glucagon was reduced prominently in the diabetic group treated with sulfonylurea. The relationship between the response of glucose and plasma insulin and between glucose and glucagon to arginine was investigated, and the importance of the changes in the insulin:glucagon ratio was emphasized. Moreover, the possibility that long-term administration of a sulfonylurea may reduce an exaggerated glucagon response to arginine was discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1158041     DOI: 10.2337/diab.24.9.811

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Plasma glucagon in insulinoma.

Authors:  A Ohneda; K Matsuda; K Horigome; S Ishii; A Yanbe; Y Maruhama
Journal:  Acta Diabetol Lat       Date:  1977 Sep-Dec

Review 2.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

3.  Dose-kinetics of pancreatic glucagon responses to arginine and glucose in subjects with normal and impaired pancreatic B cell function.

Authors:  R Assan; S Efendic; R Luft; E Cerasi
Journal:  Diabetologia       Date:  1981-11       Impact factor: 10.122

4.  Effect of somatostatin on metabolic and hormonal changes induced by nicotinic acid in insulin-dependent diabetics.

Authors:  A S Luyckx; P J Lefebvre
Journal:  Diabetologia       Date:  1976-10       Impact factor: 10.122

5.  Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs.

Authors:  A Ohneda; T Kobayashi; J Nihei
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

6.  Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations.

Authors:  S E Fineberg; S H Schneider
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

7.  Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion.

Authors:  E Lien; D Sarantakis
Journal:  Diabetologia       Date:  1979-07       Impact factor: 10.122

8.  Insulin and glucagon in spontaneously diabetic non-obese mice.

Authors:  A Ohneda; T Kobayashi; J Nihei; Y Tochino; H Kanaya; S Makino
Journal:  Diabetologia       Date:  1984-10       Impact factor: 10.122

9.  The Impact of Amino Acids on Postprandial Glucose and Insulin Kinetics in Humans: A Quantitative Overview.

Authors:  Bart van Sloun; Gijs H Goossens; Balazs Erdos; Michael Lenz; Natal van Riel; Ilja C W Arts
Journal:  Nutrients       Date:  2020-10-21       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.